Brief: Adocia's Partner Tonghua Dongbao Receives Clearance To Start Biochaperone® Lispro Phase 3 Trial in China

Adocia SA

14/10/2021 06:34

Oct 14 (Reuters) - Adocia SA  ADOC.PA :
    * ADOCIA’S PARTNER TONGHUA DONGBAO RECEIVES CLEARANCE TO
START
ULTRA-RAPID INSULIN BIOCHAPERONE® LISPRO PHASE 3 TRIAL TO TREAT
TYPE 1 AND TYPE 2 DIABETES IN CHINA
    * THIS PHASE 3 CLINICAL PROGRAM WILL ENROLL OVER 1,300
PEOPLE WITH
DIABETES AND IS EXPECTED TO BE PIVOTAL FOR PRODUCT REGISTRATION
IN CHINA
    * FIRST PATIENT IN THE STUDY WILL TRIGGER A MILESTONE
PAYMENT TO
ADOCIA
    * BC LISPRO ADDRESSES THE CHINESE PRANDIAL INSULIN MARKET
WHICH IS
APPROX. $1.4BN TODAY WITH DOUBLE-DIGIT GROWTH
    * THE TOTAL AMOUNT PERCEIVED FOR THIS AGREEMENT COULD REACH
$45M
(INCLUDING $10M UPFRONT PAYMENT) AND DOUBLE-DIGIT ROYALTIES ON
SALES

Source text for Eikon:  ID:nBw8d5jVta 
Further company coverage:  ADOC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))